Introduction:
The SCNIR (the Registry) opened in 1994. The original goal was to collect data on the safety of long-term administration of G-CSF (Neupogen) to adults and children with severe chronic neutropenia (SCN) for reports to the Food and Drug Administration (FDA) and European Medicines Agency (EMA). Over time, the SCNIR has become an invaluable resource for understanding the genetic and molecular basis for chronic neutropenia and the outcomes of long term treatment of neutropenia with Neupogen/G-CSF and other therapies.

Patients:
There are currently 1647 subjects enrolled through the Seattle SCNIR office. Figure 1 shows the distribution by diagnostic category: congenital, cyclic, idiopathic and autoimmune neutropenia for SCNIR/Seattle:

![Figure 1](image1.png)

New Enrollees:
Figure 2 shows the number of new subjects enrolled by the SCNIR/Seattle for the years 2007 through 2017. The range is 41 to 77 subjects, mean 56 subjects.

![Figure 2](image2.png)
Publications:
This list includes papers, chapters, editorials, commentaries and abstracts published from the SCNIR and its Advisory Board for the period 2014 to the present.

Research Reports

2014


2015


2016


2017


INVITED REVIEWS AND CHAPTERS:

EDITORIALS, COMMENTARIES AND LETTERS

ABSTRACTS:


